Henry Schein (HSIC)
NASDAQ: HSIC · Health Care Distributors · Melville, NY
Our rating: Positive
Call changed from Neutral to Positive at $88.24, moderate conviction, November 4, 2026.
Breaks if: The Positive call loses its support if trailing-twelve-month free cash flow falls below $550M — compressing the FCF yield to under 5.6% at today's price — in any quarterly report through the end of 2027, or if year-over-year revenue growth prints below 2% for two consecutive quarters. Either outcome would signal that the cash-generative franchise the view rests on is weakening structurally, not simply reflecting an earnings-timing mismatch.
Key figures
| Market value | $9.2B |
|---|---|
| Revenue, last 12 months | $13.7B |
| Net income, last 12 months | $421M |
| Free cash flow, last 12 months | $559M |
| Price to earnings | 21.9× |
| Free cash flow yield | 6.1% |
| Dividend yield | 0.0% |
| Operating margin | 5.2% |
| Return on equity | 12.9% |
| Beta to the S&P 500 | 0.55 |
| Volatility, annualized | 27.4% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 26, 2026 | $3.5B | 4.0% | $1.06 | $131M |
| June 27, 2026 | $3.5B | 6.7% | $0.82 | $212M |
| March 28, 2026 | $3.4B | 6.3% | $0.92 | −$122M |
| December 27, 2025 | $3.4B | 7.7% | $0.85 | $338M |
| September 27, 2025 | $3.3B | 5.2% | $0.84 | $141M |
| June 28, 2025 | $3.2B | 3.3% | $0.70 | $88M |
| March 29, 2025 | $3.2B | −0.1% | $0.88 | $6M |
| December 28, 2024 | $3.2B | 5.8% | $0.75 | $168M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.65B: Claude 35%, Gemini 60%, Mistral 38%
- Diluted earnings per share are at least $0.85: Claude 52%, Gemini 90%, Mistral 70%
- Free cash flow for the quarter is at least $0.34B: Claude 38%, Gemini 35%, Mistral 35%
10 ledger entries and 53 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.